Beginning in February 2015, Lieff Cabraser conducted an extensive investigation into dramatic price increases of certain generic drugs. Lieff Cabraser worked alongside economists and industry experts and interviewed industry participants to evaluate possible misconduct. In December of 2016, Lieff Cabraser, with co-counsel, filed the first case alleging price-fixing of levothyroxine, the primary treatment for hypothyroidism, among the most widely prescribed drugs in the world.
Lieff Cabraser also played a significant role in similar litigation over the drug propranolol in the Southern District of New York.
On May 19, 2017, Elizabeth Cabraser was named to the End-Payer Plaintiffs’ Plaintiff Steering Committee in In Re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 (E.D. Pa.). In that case, Lieff Cabraser represents 10 health and welfare funds covering tens of thousands of individuals in litigation alleging that various drug companies conspired to keep producers of generic versions of numerous drugs from competing against each other. The case is in its earliest stages.